Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024
STONY BROOK, NY / ACCESSWIRE / February 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...
Genetic Testing
Applied DNA Announces Closing of $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
STONY BROOK, NY / ACCESSWIRE / February 2, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in...
Applied DNA Announces $3.44 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
STONY BROOK, NY / ACCESSWIRE / January 31, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in...
Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing
Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome mapping (OGM) that...
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual...
Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and...
TOUCHBBCA Joins the Carebox Connect Network
When We Tri(al) by TOUCH, The Black Breast Cancer Alliance has partnered with Carebox to provide Breasties, caregivers, and the...
Mainz Biomed Provides Year-End Corporate Review 2023
European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced...
International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications
Framework was co-authored by an international consortium made up of 18 cancer researchers Publication includes researchers’ recommendations for laboratories planning...
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital...
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial Guidance
Scott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler...
Applied DNA Announces Joint Development Agreement to Integrate Linea(TM) IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with...
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / December 7, 2023 /...
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...
Texas Family Wellness Clinic Selects Sunoh.ai, Ambient Listening Technology for Clinical Documentation
The primary care facility seeks to accelerate clinical documentation while maintaining high-quality patient care and boosting overall clinic efficiencyWESTBOROUGH, Mass.--(BUSINESS...
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
STONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing...
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer...
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
- Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA -- Extension Enabled by the Company's...
Incite Health, Inc. Introduces Pharmacogenomics Services to Improve the Safety, Efficacy, and Efficiency of Clinical Trials
New innovative clinical services to help pharmaceutical and biotech companies improve patient recruitment, reduce the risk of adverse reactions, and...